Goldman Sachs raises Argenx target to EUR 982: Argenx stock gains 1.50 percent

Published on 10/06/2026 at 12:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 1.50 billion in 2026. Argenx stock costs EUR 827.20 on October 6, 2026 after EUR 815.00.

Fotorealistisches Laborpanorama: Wissenschaftler in weißen Kitteln begutachten leuchtende Antikörper-3D-Modelle auf Bildschirmen, Stahltische mit Laborgeräten im Hintergrund — Argenx NL0010832176 Forscher analysieren im modernen Biopharma-Labor leuchtende Antikörper-Strukturen auf großen Monitoren, Illustration mit AI erstellt.

Argenx stock (ISIN NL0010832176) was trading at EUR 827.20 at Lang & Schwarz on October 6, 2026 at 12:34 p.m. CEST, up 1.50 percent versus the prior close of EUR 815.00. On September 25, 2026, Goldman Sachs raised its price target from EUR 973.00 to EUR 982.00 and kept a Buy rating, as Finanznachrichten reported.

Goldman raises the valuation bar

The revised target puts Goldman Sachs at EUR 9.00 above its previous mark. Against the Lang & Schwarz price, the new target lies 18.73 percent higher, using the same euro currency for both values.

The analyst action matters because it raises the reference point ahead of Argenx's next commercial update. Goldman analyst Rajan Sharma cited potential upside surprises in market expectations for VYVGART and referred to the company's quarterly report scheduled for October 22, 2026, according to Finanznachrichten.

VYVGART supplies the growth engine

At the Wells Fargo Healthcare Conference on September 8, 2026, Argenx said revenue reached USD 1.50 billion in the second quarter of 2026. Investing.com reported that growth came from VYVGART sales in myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and seronegative myasthenia gravis.

Management also described positive late-stage myositis data and a broader pipeline strategy. The company is targeting 50,000 patients across 10 diseases and five late-stage molecules by 2030, while the Forte Biosciences acquisition adds the FB102 program to its immunology portfolio, according to Investing.com.

Stock gains as valuation meets execution

The October 6 quote places Argenx EUR 12.20 above its Lang & Schwarz prior close. That daily move is smaller than the 18.73 percent gap to Goldman's target, leaving upcoming revenue delivery and pipeline progress as the measurable tests for the higher valuation.

Argenx is listed on Euronext Brussels under ticker ARGX.BR and ISIN NL0010832176, according to Global Banking and Finance. Its business is centered on biotechnology and therapies for autoimmune diseases, with VYVGART as the commercial foundation.

EUR 827.20 quote sets the reference

Argenx was trading at EUR 827.20 at Lang & Schwarz on October 6, 2026 at 12:34 p.m. CEST, up 1.50 percent versus the prior close of EUR 815.00 on October 5, 2026. The further course of trading is shown by the continuously updated real-time quote of Argenx stock.